Everhart Financial Group Inc. Takes Position in SELLAS Life Sciences Group, Inc. $SLS

Key Points

• Everhart Financial Group acquired 331,150 shares (≈$533,000) of SELLAS Life Sciences (NASDAQ: SLS) in Q3, representing about 0.26% of the company; institutional investors collectively own roughly 17.38% of the stock.
• Director Katherine Bach Kalin purchased 63,400 shares at $1.59 on Nov. 19, increasing her position 154.6% to 104,400 shares, and insiders now own about 1.20% of the company.
• SLS shares opened at $3.77 (52‑week range $0.95–$5.18) with a $537M market cap and a negative P/E; the company beat quarterly EPS (-$0.06 vs. -$0.08) but analysts expect -0.57 EPS for the year and the consensus rating is "Hold" with a $7 target while Weiss Ratings maintains a "sell (d-)."

Everhart Financial Group Inc. acquired a new stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 331,150 shares of the company's stock, valued at approximately $533,000. Everhart Financial Group Inc. owned 0.26% of SELLAS Life Sciences Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blair William & Co. IL acquired a new stake in SELLAS Life Sciences Group during the second quarter worth about $35,000. ProShare Advisors LLC acquired a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at $43,000. Simon Quick Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at about $44,000. Great Valley Advisor Group Inc. acquired a new stake in SELLAS Life Sciences Group in the 2nd quarter worth about $44,000. Finally, Scissortail Wealth Management LLC acquired a new stake in shares of SELLAS Life Sciences Group in the third quarter worth approximately $44,000. Institutional investors and hedge funds own 17.38% of the company's stock.

SELLAS Life Sciences Group Stock Down 3.1%

Shares of NASDAQ SLS opened at $3.77 on Monday. SELLAS Life Sciences Group, Inc. has a 52-week low of $0.95 and a 52-week high of $5.18. The business's 50 day moving average is $3.03 and its two-hundred day moving average is $2.21. The firm has a market cap of $537.00 million, a price-to-earnings ratio of -13.46 and a beta of 2.27.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. Analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin purchased 63,400 shares of the firm's stock in a transaction on Wednesday, November 19th. The stock was bought at an average price of $1.59 per share, with a total value of $100,806.00. Following the transaction, the director directly owned 104,400 shares of the company's stock, valued at approximately $165,996. This represents a 154.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $7.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.